Darya-Varia Laboratoria Tbk

Darya-Varia Laboratoria Tbk

DVLA · JK · Healthcare / Drug Manufacturers - Specialty & Generic

1,575.00IDR+5.00 (+0.32%)

Price History

Full chart

Market Stats

Previous Close1,570.00
Open1,575.00
Day Range1,570.00 – 1,575.00
52-Week Range1,391.82 – 1,626.99
Volume7.40K
Market Cap1.78T
P/E (TTM)12.99
Forward P/E0.00
EPS122.05
Dividend Yield8.08%
Beta-0.09
50-Day Avg1,585.50
200-Day Avg1,602.03

About

PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. It also provides prescription products for various therapeutic areas, including cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women healthcare, antiparasit, vitamin and food supplements, anti fungal, plastic surgery, general surgery, burn, trauma wound, aesthetic medicine, somatik, ear healthcare, and central nerve systems. In addition, the company offers toll manufacturing services for soft gelatin capsules, as well as sterile injections and low volume solid products. It also exports its products. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk operates as a subsidiary of Blue Sphere Singapore Pte. Ltd.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Ian Martin Wibawa Kloer
  • Employees1.36K
  • HeadquartersTower C, Jakarta, Indonesia, 12430, Indonesia
  • Websitehttps://www.darya-varia.com

Leadership

  • Dr. Ian Martin Wibawa KloerPresident Director · b. 1974
  • Mr. Celso Paz LimFinance Director & Director · b. 1969
  • Ms. Widya Olivia TobingHead of Legal & Corporate Affairs Division and Corporate Secretary · b. 1976
  • Mr. Dandan DarmawanDirector of Human Resources Development
  • Mr. Chandra Ngesahkan Halomoan TariganHead of Internal Audit Unit · b. 1979
  • Mr. Setyo DumadiTreasury · b. 1977

Financials

Income Statement

Currency: IDR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue430.70B509.62B549.02B390.35B426.80B540.44B576.67B509.50B577.60B869.17B929.20B972.30B1.09T1.10T1.10T1.31T1.45T1.58T1.70T1.81T1.83T1.90T1.92T1.89T2.09T2.23T
Growth (%)-+18.32%+7.73%-28.90%+9.34%+26.63%+6.70%-11.65%+13.37%+50.48%+6.91%+4.64%+11.84%+1.32%+0.19%+18.33%+11.12%+8.56%+7.87%+6.67%+0.92%+3.89%+0.85%-1.36%+10.40%+6.90%
Cost of Revenue223.91B274.76B269.30B119.22B130.55B172.86B183.60B172.86B192.94B333.09B341.55B349.02B436.27B441.03B518.60B628.36B649.92B681.69B774.25B839.54B897.71B905.13B910.92B915.65B990.58B1.06T
Gross Profit---------536.08B587.65B623.28B651.11B660.66B585.22B677.73B801.44B893.96B925.41B973.48B931.99B995.77B1.01T975.24B1.10T1.17T
Gross Margin---------61.68%63.24%64.10%59.88%59.97%53.02%51.89%55.22%56.74%54.45%53.69%50.94%52.38%52.48%51.58%52.55%52.61%
Operating Expense---------416.75B450.56B463.10B454.94B493.58B490.75B550.99B597.81B673.99B658.10B676.86B721.27B787.17B807.78B785.19B890.62B964.60B
Operating Income43.91B49.68B67.03B72.27B77.20B72.90B75.51B63.94B71.62B119.33B137.09B160.18B196.17B167.08B94.47B126.74B203.63B219.97B267.31B296.62B210.72B208.60B198.35B190.05B206.40B209.48B
Operating Margin10.20%9.75%12.21%18.51%18.09%13.49%13.09%12.55%12.40%13.73%14.75%16.47%18.04%15.17%8.56%9.70%14.03%13.96%15.73%16.36%11.52%10.97%10.35%10.05%9.89%9.39%
EBITDA---------119.33B150.02B160.18B218.33B159.37B108.20B128.22B255.25B273.46B297.08B352.99B271.08B272.75B262.89B255.92B246.44B282.82B
EBITDA Margin---------13.73%16.15%16.47%20.08%14.47%9.80%9.82%17.59%17.36%17.48%19.47%14.82%14.35%13.71%13.53%11.80%12.67%
Net Income--63.53B46.39B49.81B71.58B52.51B49.92B70.82B72.27B110.88B120.92B148.91B125.80B80.93B107.89B152.08B162.25B200.65B221.78B162.07B146.51B149.38B146.34B156.15B163.95B
Net Income Margin--11.57%11.89%11.67%13.24%9.11%9.80%12.26%8.32%11.93%12.44%13.69%11.42%7.33%8.26%10.48%10.30%11.81%12.23%8.86%7.71%7.79%7.74%7.48%7.35%
R&D-----------------24.16B23.17B23.67B26.30B40.30B25.01B30.66B--
R&D as % of Total Revenue-----------------1.53%1.36%1.31%1.44%2.12%1.30%1.62%--
Interest Expense000000000000398.89M419.78M523.29M425.10M466.16M39.49M498.63M429.56M427.62M500.78M505.69M381.42M348.94M322.80M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.04%0.04%0.05%0.03%0.03%0.00%0.03%0.02%0.02%0.03%0.03%0.02%0.02%0.01%

Balance Sheet

Currency: IDR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets376.28B380.44B322.92B373.56B431.17B550.63B557.34B560.93B637.66B783.61B854.11B928.29B1.07T1.19T1.24T1.38T1.53T1.64T1.68T1.83T1.99T2.09T2.01T2.04T2.16T2.35T
Total Liabilities206.10B216.89B95.84B100.08B112.15B160.03B145.03B98.70B129.81B228.69B213.51B200.37B233.14B275.35B273.82B402.76B451.79B524.59B482.56B523.88B660.42B705.11B605.52B637.74B712.57B873.13B
Total Equity170.17B163.55B227.09B273.48B319.03B390.60B412.31B462.23B507.85B554.92B640.60B727.92B841.55B914.70B962.43B973.52B1.08T1.12T1.20T1.31T1.33T1.39T1.40T1.40T1.45T1.48T
Cash14.10B18.60B51.74B68.33B90.48B166.46B167.71B164.66B213.49B183.74B252.47B256.48B292.91B316.70B321.86B422.26B372.38B450.88B306.12B339.05B265.31B583.30B357.02B240.04B357.82B341.56B
Total Debt-------------11.16B------988.53M22.98B1.89B1.47B1.04B206.87M
Net Debt----------183.74B-252.47B-256.48B-292.91B-305.55B-321.86B-422.26B-372.38B-450.88B-306.12B-339.05B-264.32B-560.31B-355.13B-238.57B-356.78B-341.35B

Cash Flow

Currency: IDR2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow31.99B39.39B61.50B67.93B55.67B74.21B59.09B93.49B141.00B5.69B130.61B72.52B119.21B106.93B104.44B214.17B187.48B230.74B26.63B272.54B106.58B435.33B-16.06B109.19B331.76B201.14B
Investing Cash Flow--43.37B--17.90B----19.89B-31.82B-34.19B-52.23B-53.93B-55.39B-38.63B-197.17B-41.31B-59.26B-125.23B-60.58B-13.76B-56.99B-90.89B-93.53B-100.02B
Financing Cash Flow----------27.05B-32.96B-33.60B-35.28B-41.48B-44.36B-78.11B-39.06B-111.59B-119.36B-113.38B-119.90B-103.45B-153.60B-136.00B-121.39B-121.38B
Capital Expenditure20.30B23.34B15.93B14.43B21.84B22.13B13.03B35.15B42.65B21.58B52.59B66.09B54.94B54.94B60.59B36.95B195.96B38.40B45.49B58.96B62.81B86.99B58.18B97.92B102.65B107.32B
Free Cash Flow----------15.89B78.02B6.42B64.26B51.99B43.84B177.21B-8.49B192.34B-18.86B213.58B43.78B348.34B-74.24B11.27B229.11B93.82B
Dividends Paid------30.80B-25.20B25.20B25.20B33.60B35.28B52.64B24.64B78.11B39.06B111.59B119.41B119.62B119.84B125.44B129.92B135.52B120.96B120.96B
FCF to OCF----------279.38%59.73%8.86%53.91%48.62%41.98%82.75%-4.53%83.36%-70.83%78.37%41.07%80.02%462.29%10.32%69.06%46.65%
Dividend Paid to FCF----------158.56%32.30%522.97%54.90%101.24%56.20%44.08%-460.17%58.02%-633.13%56.01%273.75%36.01%-174.99%1202.50%52.79%128.92%

Earnings

Report DateMar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jul 30, 2013Nov 28, 2013Feb 26, 2014Apr 4, 2014Jul 29, 2014Nov 27, 2014Feb 25, 2015Apr 3, 2015Jul 28, 2015Nov 26, 2015Mar 2, 2016Apr 8, 2016Jul 26, 2016Oct 28, 2016Mar 30, 2017May 2, 2017Jul 28, 2017Oct 31, 2017Mar 26, 2018Apr 6, 2018Jul 24, 2018Nov 29, 2018Feb 27, 2019Apr 5, 2019Jul 30, 2019Nov 28, 2019Feb 26, 2020Apr 3, 2020Jul 28, 2020Nov 2, 2020Mar 3, 2021Apr 2, 2021Aug 27, 2021Nov 19, 2021May 30, 2022Aug 23, 2022Nov 7, 2022May 1, 2023Jul 28, 2023
EPS Estimate--------------------------------------------
EPS Actual32.7741.2323.1335.8139.1031.1214.6927.41-15.5560.4124.742.7653.6215.6518.329.0950.7024.0448.3813.1774.8933.6045.97-9.0856.3240.7349.2333.5274.5627.3457.1739.4750.4573.657.4413.2072.2546.78120.31122.3328.86-3.6154.3931.61
Surprise--------------------------------------------
Timing------------------Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market--------------------

Key Statistics & Ratios

Market Cap1.78T
Enterprise Value1.30T
Trailing P/E12.99
Forward P/E0.00
Price / Sales0.75
Price / Book1.18
EPS122.05
Book Value1,339.36
Revenue (TTM)2.35T
Gross Profit (TTM)1.22T
EBITDA246.78B
Profit Margin5.79%
Operating Margin8.16%
Return on Equity9.10%
Return on Assets4.34%
Shares Outstanding1.12B
Shares Float88.27M
Beta-0.09
Dividend Yield8.08%
Dividend Rate128.00
Payout Ratio86.07%

Dividends

20261×
64.00Jun 30, 2026
20252×
41.00Oct 30, 202567.00Jun 30, 2025
20242×
43.00Nov 1, 202465.00Jun 24, 2024
20233×
43.00Nov 13, 202378.00Jul 6, 2023100000.00Jul 4, 2023
20222×
41.00Nov 3, 202275.00Jul 7, 2022
20212×
39.00Nov 3, 202173.00Jun 24, 2021
20202×
37.00Nov 9, 202070.00Jul 15, 2020
20192×
37.00Nov 1, 201970.00Jun 20, 2019
20182×
37.00Oct 3, 201870.00May 16, 2018
20172×
35.00Aug 25, 201765.00Jun 14, 2017
20161×
35.00Jun 2, 2016
20152×
30.00Sep 15, 201540.00Jun 11, 2015
20141×
22.00Jun 24, 2014

Stock Splits

  • Nov 12, 20102:1